Sell 11/11/2024Downgrade
Nuvectis Pharma, Inc. (NVCT) was downgraded to E+ from D- on 11/11/2024 due to a decline in the volatility index and valuation index.

Sell 11/8/2024Upgraded
Nuvectis Pharma, Inc. (NVCT) was upgraded to D- from E+ on 11/8/2024 due to an increase in the total return index and volatility index.

Sell 9/30/2024Downgrade
Nuvectis Pharma, Inc. (NVCT) was downgraded to E+ from D- on 9/30/2024 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 3.42 to 3.14.

Sell 5/3/2024Upgraded
Nuvectis Pharma, Inc. (NVCT) was upgraded to D- from E+ on 5/3/2024 due to an increase in the growth index and volatility index. EBIT increased 4.74% from -$6.16M to -$5.87M.

Sell 11/10/2023Downgrade
Nuvectis Pharma, Inc. (NVCT) was downgraded to E+ from D- on 11/10/2023 due to a noticeable decline in the total return index, growth index and volatility index. EBIT declined 6.69% from -$5.77M to -$6.16M.

Sell 5/2/2023Upgraded
Nuvectis Pharma, Inc. (NVCT) was upgraded to D- from E+ on 5/2/2023 due to a major increase in the total return index and volatility index.

Sell 3/14/2023Downgrade
Nuvectis Pharma, Inc. (NVCT) was downgraded to E+ from D on 3/14/2023 due to a decline in the solvency index, valuation index and total return index. The quick ratio declined from 5.26 to 3.23.

Sell 3/1/2023Upgraded
Nuvectis Pharma, Inc. (NVCT) was upgraded to D from D- on 3/1/2023 due to an increase in the volatility index and solvency index. The quick ratio increased from 4.96 to 5.26.

Sell 11/1/2022Upgraded
Nuvectis Pharma, Inc. (NVCT) was upgraded to D- from E on 11/1/2022 due to an increase in the valuation index.

Sell 8/22/2022Downgrade
Nuvectis Pharma, Inc. (NVCT) was downgraded to E from E+ on 8/22/2022 due to a decline in the volatility index, efficiency index and total return index. Net income declined 21.27% from -$2.94M to -$3.57M, and total capital declined 21.01% from $14.56M to $11.5M.

Sell 8/1/2022Upgraded
Nuvectis Pharma, Inc. (NVCT) was upgraded to E+ from E on 8/1/2022 due to a significant increase in the solvency index, total return index and efficiency index. Total capital increased 243.53% from $4.24M to $14.56M, and the quick ratio increased from 2.37 to 5.46.

Sell 5/2/2022None
Nuvectis Pharma, Inc. (NVCT) was downgraded to E from U on 05/02/2022.